Who are Topical cyclopentolate and phenylephrine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/topical-cyclopentolate-and-phenylephrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Topical cyclopentolate and phenylephrine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical cyclopentolate and phenylephrine (Topical cyclopentolate and phenylephrine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent + alpha-1 adrenergic agonist. Area: Ophthalmology.

marketed Anticholinergic agent + alpha-1 adrenergic agonist Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Topical cyclopentolate and phenylephrine (Topical cyclopentolate and phenylephrine) — Dar El Oyoun Hospital. Cyclopentolate blocks muscarinic acetylcholine receptors to cause mydriasis and cycloplegia, while phenylephrine stimulates alpha-1 adrenergic receptors to enhance mydriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Topical cyclopentolate and phenylephrine TARGET	Topical cyclopentolate and phenylephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent + alpha-1 adrenergic agonist	Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent + alpha-1 adrenergic agonist class)

Dar El Oyoun Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Topical cyclopentolate and phenylephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/topical-cyclopentolate-and-phenylephrine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing